A simple multiplex real-time PCR methodology for the SMN1 gene copy number quantification.

Spinal muscular atrophy (SMA) is an autosomal recessive disease caused, in about 95% of SMA cases, by homozygous deletion of the survival motor neuron 1 (SMN1) gene or its conversion to the highly homologous SMN2 gene. The molecular diagnosis of SMA is usually carried out by a PCR-Restriction fragment length polymorphism (RFLP) approach. However, this approach is not useful for identification of healthy deletion carriers. TaqMan technology is one of the most reliable and widely adopted techniques for the SMN1 copy number evaluation. However, several limitations of this technique have been described. Particularly, DNA extraction methods and accurate template quantification have been shown to be critical for reliable results. In this work, we set up a reliable, highly reproducible, and easy-to-perform TaqMan technology-based protocol to obtain the SMN1 gene copy number assessment. We demonstrate that PCR amplification of both target gene and reference gene in the same reaction mix, instead of separated mixes, greatly reduces reported criticisms of simplex TaqMan technology. The multiplex real-time PCR we describe allows interlaboratory samples and data exchange, without the need to equalize the DNA isolation technique. Further, the protocol described below requires fewer replica tests than the simplex methodology does, leading to reduced overall cost for the diagnostic assay.

[1]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[2]  A. Emery.  Population frequencies of inherited neuromuscular diseases—A world survey , 1991, Neuromuscular Disorders.

[3]  E. Zapletalová,et al.  Analysis of point mutations in the SMN1 gene in SMA patients bearing a single SMN1 copy , 2007, Neuromuscular Disorders.

[4]  A. Burghes.  When is a deletion not a deletion? When it is converted. , 1997, American journal of human genetics.

[5]  P. Seeman,et al.  Quantitative multiplex real-time PCR for detection of PLP1 gene duplications in Pelizaeus-Merzbacher patients. , 2006, Genetic testing.

[6]  O. Clermont,et al.  Prevalence of SMN1 deletion and duplication in carrier and normal populations: implication for genetic counselling , 2003, Journal of medical genetics.

[7]  T. Wienker,et al.  Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. , 2002, American journal of human genetics.

[8]  G. Matthijs,et al.  Genotype determination at the survival motor neuron locus in a normal population and SMA carriers using competitive PCR and primer extension , 2000, Human mutation.

[9]  A. Czeizel,et al.  A hungarian study on Werdnig-Hoffmann disease. , 1989, Journal of medical genetics.

[10]  Shuji Ogino,et al.  Genetic testing and risk assessment for spinal muscular atrophy (SMA) , 2002, Human Genetics.

[11]  C. Lorson,et al.  A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Munsat.  International SMA consortium meeting , 1992 .

[13]  T. Wienker,et al.  Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. , 1999, American journal of human genetics.

[14]  N. Darín,et al.  Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy , 2006, Neuromuscular Disorders.

[15]  J. McPherson,et al.  A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. , 1999, Human molecular genetics.

[16]  S. Halvorsen,et al.  Child neuromuscular disease in Southern Norway: Prevalence, age and distribution of diagnosis with special reference to “non‐Duchenne muscular dystrophy” , 1988, Clinical genetics.

[17]  Karyn G. Robinson,et al.  Robust quantification of the SMN gene copy number by real-time TaqMan PCR , 2009, neurogenetics.

[18]  A. Munnich,et al.  Structure and organization of the human survival motor neurone (SMN) gene. , 1996, Genomics.

[19]  W. Ewens,et al.  Genetic risk assessment in carrier testing for spinal muscular atrophy. , 2002, American journal of medical genetics.

[20]  D. Zwijnenburg,et al.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.

[21]  J. Weissenbach,et al.  Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.

[22]  B. Dallapiccola,et al.  Spinal muscular atrophy genotyping by gene dosage using multiple ligation-dependent probe amplification , 2006, Neurogenetics.

[23]  I. Cusco,et al.  Implementation of SMA carrier testing in genetic laboratories: comparison of two methods for quantifying the SMN1 gene , 2002, Human mutation.

[24]  T. Munsat,et al.  International SMA Consortium Meeting (26–28 June 1992, Bonn, Germany) , 1992, Neuromuscular Disorders.

[25]  K. Zerres,et al.  Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. , 1995, Archives of neurology.

[26]  K. Zerres,et al.  Determination of SMN1 and SMN2 copy number using TaqMan™ technology , 2003, Human mutation.

[27]  J. Osinga,et al.  PCR-based DNA test to confirm clinical diagnosis of autosomal recessive spinal muscular atrophy , 1995, The Lancet.

[28]  R. Pyatt,et al.  A feasibility study for the newborn screening of spinal muscular atrophy , 2006, Genetics in Medicine.

[29]  V. Chan,et al.  Carrier incidence for spinal muscular atrophy in southern Chinese , 2004, Journal of Neurology.